ArticleScientific reports2025
Detection and isolation of viable cancer cells mediated by spytag and spycatcher using conditionally replicative adenovirus and magnetic microbeads.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Circulating tumor cells (CTCs) are critical biomarkers for cancer diagnosis, prognosis, and therapy monitoring, but their rarity and reliance on surface markers limit detection and isolation. While conditionally replicative adenoviruses (crADs) enable tumor-selective targeting, their use has been limited to fluorescence-based detection without robust isolation of viable cells. To overcome this, we developed a crAD-based platform integrating SpyTag/SpyCatcher technology with SpyCatcher-decorated magnetic microbeads for marker-independent CTC detection and isolation. The engineered adenovirus (CR-Ad5-ST-GFP) selectively replicates in telomerase-positive tumor cells, expressing green fluorescent protein (GFP) and SpyTag under independent promoters. By leveraging the SpyTag/SpyCatcher interaction, our platform isolates CTCs without relying on surface markers, addressing epithelial-to-mesenchymal transition (EMT) and phenotype variations. In proof-of-concept experiments, A-549 and Ca Ski cells spiked into peripheral blood mononuclear cells (PBMCs) at 1:10,000 were detected and isolated with over 80% efficiency. The isolated cells remained viable and were successfully re-cultured, demonstrating their potential for downstream applications such as molecular profiling and drug sensitivity testing. This method advances crAD-based approaches by combining tumor-selective viral targeting with marker-independent, viable CTC isolation. Its compatibility with microfluidic systems makes it a promising tool for tumor monitoring and personalized cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.